Crossref
Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies
Journal of Bioinformatics and Systems Biology · 2021
DOI: 10.26502/jbsb.5107021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bioinformatics and Systems Biology, 2021. Verfasst von Akash Parab und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Parab, A., Kaur, D. G., Sharma, A., Bhuller, G., Chitnis, S., Chindaliya, A., & Weta, M. (2021). Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies. Journal of Bioinformatics and Systems Biology. https://doi.org/10.26502/jbsb.5107021
Vancouver
Parab A, Kaur DG, Sharma A, Bhuller G, Chitnis S, Chindaliya A, et al. Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies. Journal of Bioinformatics and Systems Biology. 2021. doi:10.26502/jbsb.5107021
BibTeX
@article{Parab2021,
author = {Parab, Akash and Kaur, Dr Gaganjyot and Sharma, Abhishek and Bhuller, Gursewak and Chitnis, Sharvari and Chindaliya, Ankit and Weta, Mayur},
title = {Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies},
journal = {Journal of Bioinformatics and Systems Biology},
year = {2021},
doi = {10.26502/jbsb.5107021}
}
EUVIMED